Skin Rash Occurring with Olanzapine Pamoate, but not with Oral Olanzapine, in a Male with Juvenile Idiopathic Arthritis

Solfanelli, Andrea; Curto, Martina; Dimitri-Valente, Giorgia; Kotzalidis, Georgios D.; Gasperoni, Carlotta; Sani, Gabriele; Manfredi, Giovanni; Rapinesi, Chiara; Comparelli, Anna; Girardi, Paolo

doi:10.1089/cap.2012.0121

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies of patients with anxiety disorders have found evidence of this altered amygdala connectivity, specifically in youth (Hamm et al, 2014; Swartz, Phan, Angstadt, Fitzgerald, & Monk, 2014). Schizophrenia patients also show altered amygdala activity during social tasks and facial recognition studies, with a higher activation to neutral faces and lower activation to fearful ones as compared to controls (Mier et al, 2014; Morris et al, 1996; Mukherjee et al, 2013; Solfanelli et al, 2013). This has led to the hypothesis that dysfunction of the amygdala is closely related to the social impairments seen in schizophrenia patients due to inappropriate activation to normally non-fearful social stimuli.…”

Section: Introductionmentioning

confidence: 99%

Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.

Sobota¹,

Mihara²,

Forrest³

et al. 2015

Behavioral Neuroscience

View full text Add to dashboard Cite

Standard dopamine therapies for schizophrenia are not efficacious for negative symptoms of the disease, including asociality. This reduced social behavior may be due to glutamatergic dysfunction within the amygdala leading to increased fear and social anxiety. Several studies have demonstrated the pro-social effects of oxytocin in schizophrenia patients. Therefore, this study evaluates the effect of sub-chronic oxytocin on electroencephalographic (EEG) activity in amygdala of mice during performance of the three chamber social choice and open field tests following acute ketamine as a model of glutamatergic dysfunction. Oxytocin did not restore social deficits introduced by ketamine, but did significantly increase sociality in comparison to the control group. Ketamine had no effect on time spent in the center during the open field trials, while oxytocin increased overall center time across all groups, suggesting a reduction in anxiety. Amygdala activity was consistent across all drug groups during social and nonsocial behavioral trials. However, oxytocin reduced overall amygdala EEG power during the two behavioral tasks. Alternatively, ketamine did not significantly affect EEG power throughout the tasks. Decreased EEG power in the amygdala, as caused by oxytocin, may be related to both reduced anxiety and increased social behaviors. Data suggest that separate pro-social and social anxiety pathways may mediate social preference.

show abstract

Section: Introductionmentioning

confidence: 99%

Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.

Sobota¹,

Mihara²,

Forrest³

et al. 2015

Behavioral Neuroscience

View full text Add to dashboard Cite

show abstract

“…Looking at the single case reports, two of them were based on the description of side effects [ 44 , 45 ]. Mirza et al [ 45 ] described a male adolescent inpatient with schizophrenia who developed a severe acute-onset delirium after the second dose of LAI paliperidone (first dose: 150 mg and second: 100 mg).…”

Section: Resultsmentioning

confidence: 99%

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Background Long-acting injectable antipsychotics (LAIAs) are an efficacious and well-tolerated treatment in adults with schizophrenia spectrum disorders (SSD). However, there is less evidence for their use in children and adolescents. Objectives The aim of this systematic review was to summarize findings regarding the effectiveness and side effects of LAIA in children and adolescents with SSD. Methods Four databases (Web of Science, PubMed, MEDES, and Dialnet) were systematically searched for articles published between inception and 12 March, 2022, with the following inclusion criteria: (1) original articles or case reports; (2) providing data on efficacy/effectiveness or safety/tolerability of LAIA treatment in children and adolescents diagnosed with SSD (schizophrenia, schizoaffective disorder, schizophreniform disorder, non-affective psychotic disorder); (3) mean age of samples ≤ 18 years; and (4) written in English or Spanish. Exclusion criteria were review articles, clinical guides, expert consensus as well as posters or oral communication in conferences. The risk of bias was assessed using the ROBIS tool. Results From 847 articles found, 13 met the inclusion criteria. These included seven single case reports or case series, four retrospective chart reviews, a 24-week open-label trial, and one observational prospective study, covering a total of 119 adolescents (aged 12–17 years) with SSD. Almost all the articles described data on second-generation LAIA (53 patients on risperidone [once every other week], 33 on paliperidone palmitate [once monthly], 10 on aripiprazole [once monthly], and two on olanzapine pamoate [once monthly]). Twenty-one patients were reported to be only on first-generation LAIAs. Non-adherence was the main reason for starting an LAIA. In all of the studies, the use of LAIAs was associated with improvement in the patients’ symptoms. Conclusions There are few studies assessing the use of LAIAs in adolescents with SSD. Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability. However, we found no studies examining their use in children aged < 12 years. The problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study, ideally with prospective, controlled designs. Supplementary Information The online version contains supplementary material available at 10.1007/s40272-023-00558-x.

show abstract

“…None of the previous reports had described the postpartum onset of acneiform dermatoses on exposure to olanzapine. Skin rash, [7] pustular eruptions, [8] hypersensitivity syndrome, [9] acneform eruptions, [7] and pellagroid skin eruptions have been reported with oral olanzapine preparation [10] in non-postpartum cases. Pathological findings have confirmed the nature of the skin eruption after olanzapine exposure [11] in non-postpartum cases.There is no previous case report describing postpartum acneiform dermatosis with olanzapine exposure in schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

Dysmorphic Delusion and Olanzapine-Induced Postpartum Dermatosis in a Case of Schizophrenia

Sutar¹,

Ganjekar

2019

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Skin Rash Occurring with Olanzapine Pamoate, but not with Oral Olanzapine, in a Male with Juvenile Idiopathic Arthritis

Abstract: [No abstract available

Cited by 8 publications

References 17 publications

Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.

Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism.

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

Dysmorphic Delusion and Olanzapine-Induced Postpartum Dermatosis in a Case of Schizophrenia

Contact Info

Product

Resources

About